Key statistics
On Friday, PAVmed Inc (PAVM:NAQ) closed at 1.61, 168.38% above the 52 week low of 0.5999 set on Jun 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.73 |
---|---|
High | 1.76 |
Low | 1.54 |
Bid | 1.61 |
Offer | 2.57 |
Previous close | 1.65 |
Average volume | 112.41k |
---|---|
Shares outstanding | 10.41m |
Free float | 9.94m |
P/E (TTM) | -- |
Market cap | 16.75m USD |
EPS (TTM) | -8.17 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
- Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
- Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
- Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
- The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer
- PAVmed Provides Business Update and Second Quarter 2024 Financial Results
- Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
- Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
- Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
- Lucid Diagnostics to Participate in Upcoming Investor Conferences
More ▼